RGEN REPLIGEN CORP
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 730272 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.8%
TTM net income YoY-779.2%
TTM EPS YoY-1,150.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin53.8%
Operating margin2.3%
Net margin-1.5%
FCF margin13.2%
EBITDA margin11.9%
Returns
ROE-0.6%
ROA-0.4%
ROIC (approx.)0.5%
Asset turnover0.28x
Leverage & solvency
Liabilities / assets28.5%
Debt / equity0.27x
Current ratio9.88x
Interest coverage0.81x
Cash quality & payout
Operating cash flow / net income-11.00x
Accruals ratio-4.8%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $738.26M | $634.44M |
| Cost of revenue | $352.01M | $359.79M |
| Gross profit | $386.25M | $274.64M |
| R&D expense | $54.18M | $43.20M |
| SG&A expense | $290.51M | $263.37M |
| Operating income | $55.17M | -$35.11M |
| Interest expense | $21.51M | $20.73M |
| Pretax income | $62.38M | -$27.04M |
| Income tax | $13.49M | -$1.52M |
| Net income | $48.89M | -$25.51M |
| EBITDA | $133.91M | $34.56M |
| EPS (basic) | 0.87 | -0.46 |
| EPS (diluted) | 0.86 | -0.46 |
| Weighted avg. shares (diluted) | 56,561 | 55,937 |
| Balance sheet | ||
| Cash & equivalents | $566.02M | $757.36M |
| Short-term investments | $201.61M | $0 |
| Receivables | $158.59M | $134.12M |
| Inventory | $170.46M | $142.96M |
| Current assets | $1.14B | $1.07B |
| PP&E, net | $186.61M | $197.74M |
| Goodwill | $1.11B | $1.03B |
| Intangibles | $386.15M | $397.90M |
| Total assets | $2.95B | $2.83B |
| Current liabilities | $135.83M | $126.79M |
| Long-term debt | $542.21M | $525.57M |
| Total debt | $542.21M | $525.57M |
| Total liabilities | $843.57M | $856.95M |
| Shareholders' equity | $2.11B | $1.97B |
| Net debt | -$23.81M | -$231.79M |
| Shares outstanding | 56.33M | 56.09M |
| Cash flow statement | ||
| Operating cash flow | $117.42M | $175.39M |
| Capital expenditure | $23.52M | $25.68M |
| Free cash flow | $93.90M | $149.72M |
| Investing cash flow | -$298.47M | -$86.38M |
| Financing cash flow | -$15.21M | -$82.90M |
| Depreciation & amortization | $78.75M | $69.67M |
| Stock-based compensation | $32.60M | $48.07M |
| Share buybacks | $0 | $0 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.